Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ(TM) for Leptomeningeal Metastases On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026 GlobeNewswire January 08, 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Plus […]

Electra Provides Update on Refinery Project Progress GlobeNewswire January 08, 2026 TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”), a leader in advancing North America's critical minerals processing, is pleased to provide an update on construction progress at North America's first cobalt sulfate refinery.

North American Niobium and Critical Minerals Corp. Reports Positive Preliminary Soil-Gas Radon Survey Results at Blanchette and Bardy; Phase 2 Planned with Rapid Follow-Up Portable Bedrock Drilling Program GlobeNewswire January 08, 2026 Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North

ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business GlobeNewswire January 08, 2026 – Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA – Positioned U.S.-based biomanufacturing hub to supply genetic medicine products across North America, South America, Europe,

Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part C Cohort GlobeNewswire January 08, 2026 Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028 DURHAM, N.C., Jan. 08, 2026

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology GlobeNewswire January 08, 2026 NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 08, 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company's management team will

Profusa Adds Leading Greek Vascular Surgeon to Customer Base GlobeNewswire January 08, 2026 Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company

Midland, in Partnership with Rio Tinto Exploration Canada, Intersects New Lithium and Cesium Bearing Pegmatites During the 2025 Drilling Program on the Galinee Project GlobeNewswire January 08, 2026 MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Rio Tinto Exploration Canada Inc. (“RTEC“), is pleased to announce the

GURU Organic Energy to Report Fourth Quarter and Fiscal Year 2025 Results GlobeNewswire January 08, 2026 MONTRÉAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada's leading organic energy drink brand1, will report its financial results for the fourth quarter and fiscal year ended October 31, 2025